Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

There is increasing interest in the possible therapeutic benefits of the gasotransmitter hydrogen sulfide (H2S; sulfide), and drugs which release sulfide are currently being evaluated in both preclinical and clinical studies as treatments for conditions ranging from cancer to cardiovascular disease to inflammation. Sulfide is generally considered to act as a vasodilator, and it is therefore not surprising that the effects of sulfide donors on both systemic and pulmonary hypertension are being examined. In this review, we provide a critical evaluation of both the evidence that H2S may be of benefit in treating systemic and pulmonary hypertension, and of current hypotheses regarding the cellular mechanisms underlying sulfide’s effects on the systemic and pulmonary vascular systems.

Loading

Article metrics loading...

/content/journals/chamc/10.2174/1871525714999160201121220
2016-04-01
2024-12-23
Loading full text...

Full text loading...

/content/journals/chamc/10.2174/1871525714999160201121220
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test